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Abstract
Onchocerciasis or "river blindness" is a chronic parasitic neglected tropical disease which is
endemic both in mainland and insular Equatorial Guinea. We aim to estimate the current
epidemiological situation of onchocerciasis in Bioko Island after vector elimination in 2005
and more than sixteen years of Community Directed Treatment with Ivermectin (CDTI) by
using molecular and serological approaches for onchocerciasis diagnosis. A community-
based cross-sectional study was carried out in Bioko Island from mid-January to mid-Febru-
ary 2014. A total of 544 study participants were recruited. A complete dermatological exami-
nation was performed and three skin snips were performed in every participant for
parasitological and molecular assessments. Blood spots were also taken for determination
of Ov16 IgG4 antibodies trough an “in-house” ELISA assay. Overall, we found 15 out of 522
individuals suffering any onchocerciasis specific cutaneous lesions and 16 out of 528
(3.0%) with onchocercal nodules in the skin. Nodules were significantly associated with
age, being more common in subjects older than 10 years than in younger people (3.9% vs.
0%, p = 0.029). Regarding the onchocerciasis laboratory assessment, no positive parasito-
logical test for microfilaria detection was found in the skin snips. The calculated seropreva-
lence through IgG4 serology was 7.9%. No children less than 10 years old were found to be
positive for this test. Only one case was positive forOnchocerca volvulus (O. volvulus) after
skin PCR. The present study points out that the on-going mass ivermectin treatment has
been effective in reducing the prevalence of onchocerciasis and corroborates the interrup-
tion of transmission in Bioko Island. To our knowledge, this is the first time that accurate
information through molecular and serological techniques is generated to estimate the
onchocerciasis prevalence in this zone. Sustained support from the national program and
appropriate communication and health education strategies to reinforce participation in
PLOS Neglected Tropical Diseases | DOI:10.1371/journal.pntd.0004829 July 22, 2016 1 / 14
a11111
OPEN ACCESS
Citation: Moya L, Herrador Z, Ta-Tang TH, Rubio
JM, Perteguer MJ, Hernandez-González A, et al.
(2016) Evidence for Suppression of Onchocerciasis
Transmission in Bioko Island, Equatorial Guinea.
PLoS Negl Trop Dis 10(7): e0004829. doi:10.1371/
journal.pntd.0004829
Editor: Christian Bottomley, London School of
Hygiene and Tropical Medicine, UNITED KINGDOM
Received: December 30, 2015
Accepted: June 16, 2016
Published: July 22, 2016
Copyright: © 2016 Moya et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any
medium, provided the original author and source are
credited.
Data Availability Statement: All relevant data are
within the paper and its Supporting Information files.
Funding: This work was supported by Spanish
Agency of International Development Cooperation
(AECID), The Spanish Academy of Dermatology and
Venereology (AEDV) and the Network of Biomedical
Research on Tropical Diseases (RICET) supported
the study. The funders had no role in study design,
data collection and analysis, decision to publish, or
preparation of the manuscript.
CDTI activities are essential to ensure progress towards onchocerciasis elimination in the
country.
Author Summary
Onchocerciasis or “river blindness” is a chronic parasitic disease which is mainly found in
Sub-Saharan Africa. Onchocerciasis is endemic in both mainland and insular Equatorial
Guinea. Huge achievements have been made on onchocerciasis control in Bioko Island in
the last years, and the country is moving fast towards elimination. In the new elimination
context, monitoring and evaluation activities with more sensitive diagnostic tools become
especially necessary in order to confirm that transmission has been interrupted. Previous
data on the epidemiological situation of onchocerciasis in Bioko Island are mainly based
on microfilaria (MF) skin snip assessments. We aim to create evidence towards the fact
that onchocerciasis transmission might have been achieved in Bioko Island after more
than sixteen years of onchocerciasis control activities by using molecular and serological
technics for onchocerciasis diagnosis.
Introduction
Onchocerciasis or "river blindness" is a chronic parasitic neglected tropical disease caused by
the filarial nematode Onchocerca volvulus (O. volvulus). It is transmitted to humans through
exposure to repeated bites of infected blackflies of the genus Similium [1]. Adult worms live in
subcutaneous nodules and form deeper worm bundles, where fertilized females can produce,
during an average of ten years, millions of embryonic larvae (microfilariae) responsible for the
morbidity associated with this disease [2]. Several simulid species have been incriminated in
the transmission of O. volvulus. The complex S. damnosum and, to a lesser extent, the S. naevei
complex are the most frequently found in Africa and the Arabian Peninsula [1].
Onchocerciasis affects many systems and organs, but most important morbidity is due to
cutaneous and ophthalmologic manifestations, with different clinical grades [3]. The presence
of one or another clinical manifestation varies depending on the most prevalent parasite strain
circulating in the area: blindness tends to occur more frequently in the West African areas of
savannah while onchocerciasis cutaneous disease (OCD) prevails in African forest areas [1].
Itching is usually the first clinical manifestation of onchocerciasis in the skin, and may occur
alone or associated with OCD. Murdoch et al. (1993) described a grading system for OCD and
defined five main categories, which can coexist together: acute papular onchodermatitis,
chronic papular onchodermatitis, lichenified onchodermatitis, atrophic onchodermatitis and
depigmented onchodermatitis [3]. This classification and grading system allowed to highlight
the linkages between the different OCD forms with onchocerciasis epidemiology in different
endemic areas [4].
Traditionally, the most common method for diagnosis of onchocerciasis was the detection
of microfilariae (MF) in small, superficial skin biopsies (skin snips). However, skin snip exami-
nation is not sufficiently sensitive for detection of early infections or for diagnosis in persons
with low MF densities. The low sensitivity of this parasitological method makes it unreliable in
hypo endemic areas. So its value is insufficient to support an epidemiological decision. More
recent and sensitive approaches include antibody-based diagnostic tests and PCR. Improved
methods are needed for field diagnosis of onchocerciasis, to support efforts aimed at
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elimination of the disease [5,6]. Actually, the updated WHO guidelines (2016) for onchocercia-
sis control suggest the use of molecular tools in situations where interruption of transmission is
suspected [7].
Onchocerciasis is endemic to tropical regions both in Africa and Latin America and in the
Yemen. In Latin America, it is found in 13 foci located in 6 different countries. In 8 of the 13
foci in the region onchocerciasis elimination and transmission interruption has been achieved
thank to Onchocerciasis Elimination Program for the Americas (OEPA) efforts [8]. More than
99% of onchocerciasis infected people live in Africa. It has been estimated that 21,115,000
members of the 118,285,000 African population at risk for infection are infected. Among these,
690,000 experienced visual impairment and 220,000 were totally blind [9,10]. Between 1974
and 2002, onchocerciasis was brought under control in West Africa through the work of the
Onchocerciasis Control Program (OCP), mainly focused on by vector control. OCP was sup-
plemented by large-scale distribution of ivermectin from 1989. The African Program for the
Control of Onchocerciasis (APOC) was launched in 1995, with the aim to establish sustainable
community-based systems for distribution of ivermectin (CDTI) in those countries where
onchocerciasis was still a public health problem [11]. As a result of the success due to sustained
onchocerciasis control activities, APOC paradigm has recently changed from control to a strat-
egy of onchocerciasis elimination ‘where feasible’ [12]. In this new context, monitoring and
evaluation activities become especially necessary in order to document if the transmission has
been interrupted. The new elimination goal requires new approaches for assessment of CDTI
needs in areas with lower infection prevalence, that may not be efficiently identified by meth-
ods such us Rapid Epidemiological Mapping for Onchocerciasis (REMO) [13].
Onchocerciasis is an endemic disease both in mainland and insular Equatorial Guinea [14].
Onchocerciasis control activities started in 1989, mainly based on massive distribution of iver-
mectin, but it was only in 1998 when CDTI activities were started as part of the proposed
APOC mandate [15]. Since then, ivermectin coverages on the eligible population have ranged
yearly between 50% and 75% [16]. Despite the fact that ivermectin coverage was below 85%,
which is the coverage needed in a sustained fashion to interrupt transmission, progress towards
this goal in Bioko Island has been made. This is partially due to the success in aerial larviciding
campaign in 2005, which achieved elimination of S. yahense from Bioko Island, with no evi-
dence of vector reappearance in the following three years. No further entomological assess-
ments have been performed after 2008 [17]. Data from 1989 showed that overall
onchocerciasis prevalence (measured through MF skin snips assessment) in Bioko Island was
75.2% (range 51.9% to 87.1%). This prevalence dropped to 38.4% after eight years of treatment
with ivermectin (from 1989 to 1998), according to Mas et al [15]. The most recent available
data from the Equatoguinean Ministry of Health (MoH), based on MF skin snip assessment,
estimated a prevalence of 0–3% in Bioko Island (2013 data). Despite these achievements, the
follow-up of CDTI activities has been irregular and there is no accurate information on the cur-
rent prevalence of onchocerciasis in the whole country. Thus, we aim to estimate the current
epidemiological situation of onchocerciasis in Bioko Island after more than sixteen years of
CDTI activities, by using molecular and serological approach for onchocerciasis diagnosis. To
our knowledge, this is the first time that the current epidemiological situation of onchocerciasis
in Bioko Island is estimated by using non-traditional methods for onchocerciasis diagnosis.
Materials and Methods
Study area
The Island of Bioko is a part of the Republic of Equatorial Guinea, which also includes Rio
Muni on the mainland and the island of Annobon. It is located in the Bay of Guinea in Central
Current Situation of Onchocerciasis in Bioko Island
PLOS Neglected Tropical Diseases | DOI:10.1371/journal.pntd.0004829 July 22, 2016 3 / 14
Africa, about 40 km southwest of the Cameroon coast. The surface area of Bioko Island is of
approximately 2,017 km2, and it is about 72 km in length. Most of its 260,000 inhabitants live
in the northern part of the island. The interior of the island is covered with dense forests on the
steep slopes of volcanoes and calderas. The highest peak on the island reaches 3,011 m above
sea level. The island has a humid tropical environment. Mean daily maximum and minimum
temperatures range between 29–32°C and 19–22°C, respectively.
Study design and sample size
A cross-sectional study was conducted from mid-January to mid-February 2014. Sampling was
carried out by multistage cluster survey. The sample size was computed using Epi-Info version
3.4.1 free software considering the following parameters: 10% hypothesized prevalence and 2%
standard error. We assumed a design effect of 2 corresponding to the complex design. The ini-
tial sample size was 450. It was increased (+20%) in prevision of missing data.
n = DEFF p(1-p)/ê 2, where DEFF is the design effect, e is the desired standard error and p
is the prevalence
Firstly, twenty communities were randomly selected with probability proportional to size
(Fig 1). Second sampling units were randomly selected households from an updated census
from each community, provided by the head of the village (in rural areas) or neighbourhood
(in urban zones). In every selected household, all individuals aged 5 years or above who had
Fig 1. House-holds distribution in the study area, Bioko Island, Equatorial Guinea.
doi:10.1371/journal.pntd.0004829.g001
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permanently lived in Bioko Island during the last five years were recruited. Children from 5 to
9 years old were included in the study in order to detect exposure to O. volvulus through Ov16,
IgG4 serology test.
Data collection
A closed ended structured questionnaire was administered to every study participant by
trained medical personnel. The questionnaire was pre-tested on close areas not included in this
study for clarity and cultural acceptability. It comprised the following parts: socio-demographic
characteristics, risk factors for onchocerciasis and clinical data. Each interview was made by
house-to-house visit. If the study participant was aged less than 15 years old, the questionnaire
was answered by a parent or guardian of the teenager.
A complete dermatological examination was performed in each participant in a well-lit pri-
vate room. Palpable nodules and signs of onchocercal skin disease (onchodermatitis) were
assessed by trained health staff. Results were recorded on the form of “positive” or “negative”.
Three skin snips specimens were collected from every participant (two from right iliac crest,
one from left iliac crest). No special collection time was considered as the microfilariae of O.
volvulus are non-periodic. Two samples were immersed in normal saline solution to prevent
the preparation from drying out. Then, they were sent to the local hospital laboratory to be
read under a 10X microscope after 24 hours. Results were expressed for each individual as ‘pos-
itive’ or ‘negative’. Laboratory results were recorded on the original (field) registration form.
The third skin snip was stored at 4°C before shipping the samples to the National Centre of
Microbiology, Health Institute Carlos III (Spain), where further PCR analysis were performed.
Laboratory techniques and microbiological determinations
Parasitological study. Two skin snips (one from each iliac crest) specimens were used for
parasitological determination of O. volvulusMF under de 10x microscope after 24h of immer-
sion in saline solution. The average number of MF per skin snip was obtained as well as the
average number of mf from both iliac crests in each individual.
Serological study. Blood spots were taken from each individual for determination of Ov16
immunoglobulin G4 (IgG4) antibodies trough an “in-house” ELISA assay. The Ov16 ELISA
assay uses a recombinant antigen of O. volvulus to measure prevalence of IgG4 antibodies
[18,19]. Sterile techniques were used to collect blood onto the 5 x 5 cm area of Whatman 2 filter
paper. The saturated blood spots were dried, individually wrapped, and transported at 4°C to
the laboratory, where they were stored at −20°C until further analysis. In the laboratory, sera
were eluted from filter paper punches and used in standard ELISA assay.
Molecular study. Preparation of the DNA template: skin snip biopsies DNA were
extracted using the QIAamp DNAMini Kit with a incubation at 56°C overnight previous to
DNA extraction. DNA, was eluted with 200 μl distilled water and stored at 4°C until use.
Detection of filarial species was performed by Real Time PCR, from a modification of a
Nested Filaria PCR [20]. The amplified products were purified for sequencing using Illustra
DNA and Gel Band Purification Kit (General Electric Healthcare, England) and sequenced
using Big Dye Terminator v3.1 Cycle Sequencing in an ABI PRISM 3700 DNA Analyzer
(Applied Biosystems, U.S.A.).
Statistical analysis
The collected data from the questionnaires and lab assessments were merged with a unique indi-
vidual id and double entered into a data entry file using EpiData software, V.3.1. The data were
then transferred to SPSS version 18.0 (SPSS Inc., Chicago, Illinois, USA). Frequencies, means and
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standard deviations (SD) were computed to summarize the data. Prevalence results with 95%
confidence intervals (CI) were also calculated. Bivariate analyses by age group were performed
with χ2 test for categorical data. Where a cell value was below 5, Fisher’s exact test for two–way
tables was applied. The criterion for significance was set at p<0.05 based on a two-sided test.
Ethical considerations
The study was approved by the ethical advisory boards of the Health Institute Carlos III in Spain
and the Ministry of Health (MoH) in Equatorial Guinea (CEI PI 21_2014). The study complied
with current national and international regulations and standards for biomedical research in
human subjects. The village and neighborhood representatives were informed of the day of the
visit and the scope of the study by an official letter from the EquatoguineanMoH.Written
informed consent was obtained from all patients prior to study inclusion. Anonymity was
assured. A written statement was also included on the introductory part of the questionnaires in
which further information concerning the purpose of the study and the confidentiality of the
research information was given. The written consent was obtained from parents or guardians in
those individuals younger than 18 years old. Data were analysed in anonymous form.
Results
A total of 544 study participants were recruited for the study. From them, 319 (58.6%) were
females and up to two thirds (77.2%) were older than ten years. The 68.4% of the interviewed
had been born in Bioko Island. The 54.0% had received none or primary education.
From the adult group (defined as aged more than 15 years old, n = 420), 43.7% were mar-
ried. The 23.7% pointed out that they were working on agriculture/fishing, while 19.6% were
house-keepers, 9.5% public employees and 2.7% were hand-workers.
Significant differences by sex were found for age group, marital status, occupation and the
variable born in Bioko Island (Table 1).
Table 1. Socio-demographic characteristics of the study population, Bioko Island, Equatorial Guinea, January 2014 (n = 544).
Variables Total Males Females p value
n % n % n %
Sex Males 225 41.4 − − − − −
Females 319 58.6 − − − −
Age group 5 age 10 124 22.8 69 30.7 55 17.2 p<0.001
>10 years old 420 77.2 156 69.3 264 82.8
Born in Bioko Island Yes 368 68.4 163 74.1 205 64.5 0.018
No 170 31.6 57 25.9 113 35.5
Marital status* Married 198 56.3 77 58.3 121 55.0 0.046
Single 124 35.2 50 37.9 74 33.6
Widow 30 8.5 5 3.8 25 11.4
Occupation * Agriculture/fishing 87 23.7 40 29.6 47 20.3 p<0.001
Hand worker 10 2.7 9 6.7 1 0.4
Public employee 35 9.5 10 7.4 25 10.8
House-keeper 72 19.6 0 0.0 72 31.0
Others 163 44.4 76 56.3 87 37.5
Educational level None/Primary 292 54.0 126 56.3 166 52.4 0.372
Secondary/University 249 46.0 98 43.8 151 47.6
* only if study participant >15 years old
doi:10.1371/journal.pntd.0004829.t001
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Clinical study
The 16.4% of the interviewees referred to have suffered onchocerciasis in the past. Overall, 15
out of 522 individuals pointed out suffering any onchocerciasis specific cutaneous lesions. Dur-
ing the clinical examination, we found that 78 out of 523 individuals (14.9%) presented itching
at the time of answering the questionnaire, and 16 out of 528 (3.0%) had onchocercal nodules
in the skin. The 1.3% of the study sample (7/544) showed clinical signs of onchodermatitis
while 10/544 (1.8%) interviewees had any degree of leopard skin. Only 2 out of 544 presented
both cutaneous manifestations (onchodermatitis and leopard skin).
After stratification by age group, we found that nodules were significantly associated with
age, being more common in subjects older than 10 years than in younger people (3.9% vs. 0%,
respectively, p = 0.029). Also pruritus was more frequently found in adults (17.6%) than chil-
dren (5.9%, p = 0.002) (Table 2).
Parasitological study
Regarding laboratory results, none of the 544 skin snips assessments for MF detection was
found positive.
Molecular study
In parallel, 541 skin snips were submitted to specific skin PCR for Loa loa,Mansonella spp and
O. volvulus (3 skin samples were missing). Skin PCR test was positive in 11/541 cases (2.0%),
all of which were adults. After DNA sequencing only one case was positive for O. volvulus. The
remaining ones included: seven positive cases forMansonella perstans, two positive cases for
Mansonella streptocerca and one case with Loa Loa, which was considered to come from blood
contamination (Table 3).
Serological study
Blood samples were obtained from 531 out of 544 individuals and analyzed for identification of
Ov16 IgG4 antibodies by ELISA. Globally, the seroprevalence calculated was 7.9%, with and
CI95%: (5.9%-10.6%). From the samples studied, 43 samples were positive and 15 undefined
Table 2. Clinical characteristics of onchocerciasis of the study population, by age Bioko Island, Equatorial Guinea, January 2014.
Variables Total n Children 5 age 10 More tan 10 years p value
n % n % N %
CLINICAL CHARACTERISTICS
Previous onchocerciasis Yes 88 16.4 1 0.8 86 20.9 p<0.001
No 418 77.7 117 96.7 299 72.2
Nodules Yes 16 3 0 0.0 16 3.9 0.029
No 512 97 119 100.0 393 96.1
Pruritus Yes 78 14.9 7 5.9 71 17.6 0.002
No 445 85.1 112 94.1 333 82.4
Cutaneous lesions Yes 15 2.9 1 0,8 14 3.5 0.133
No 507 96.9 117 99,2 390 96,5
Onchodermatitis Yes 7 1.3 1 0.8 6 1.4 1.000
No 537 98.7 123 99.2 414 98.6
Leopard skin Yes 10 1.8 0 0.0 10 2.4 0.127
No 534 98.2 124 100.0 410 97.6
doi:10.1371/journal.pntd.0004829.t002
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by OV16 -ELISA (Table 3). No children less than 10 years old were found to be positive for this
test.
Preventive practices
In relation to preventive practices among our study population, we found that 274/544 individ-
uals (50.4%) referred that they had never taken the drug. Overall, 28% had taken ivermectin
more than twice in the last five years, while 15.6% had taken it less than twice. Among those
who referred to have taken ivermectin, 65.6% pointed out that they received the drug from a
community distributor. When asking about the reasons for not taking ivermectin, we observed
that the lack of information was the most common reason (29.9%), followed by not having suf-
fered the disease (20.5%), age (16.5%), not being at home at the time of the drug campaign
(14.3%) and lack of access to the drug (11.6%) (Table 4).
Children under 10 years old referred having taken ivermectin significantly less frequently
than older participants (p<0.005), while they were more likely to have taken the drug last year
than those with older age (p = 0.002). Moreover, being younger was significantly associated
with getting ivermectin from a community distributor (p = 0.023). The most frequent reason
for not taking ivermectin in children younger than 10 years old was age (41.0%) while for
adults it was mainly due to the lack of information (37.7%) (p = 0.000).
Discussion
Our study provides evidence towards the fact that onchocerciasis transmission might have
been achieved in Bioko Island after more than sixteen years of onchocerciasis control activities.
For that purpose, we describe the current epidemiological, clinical and parasitological situation
of onchocerciasis in Bioko Island by using molecular and serological technics to estimate
onchocerciasis prevalence.
O. volvulus infection prevalence before ivermectin intervention in Bioko Island was 74.5%,
and the Community Microfilarial Load (CMFL) was 28.2 microfilariae/snip [15]. In general,
our results show that, even though some onchocerciasis clinical features can still be found in
the population, there is a marked reduction in both the prevalence and the intensity of infec-
tion compared to the initiation of onchocerciasis control activities in the study area. No posi-
tive results after skin snip MF assessment were found, and less than 8% individuals were
positive for IgG4 antibodies Ov16 by ELISA test. Furthermore, none of these cases corre-
sponded to children under 10 years old. Only one PCR-skin test was positive for O. volvulus.
Table 3. Laboratory assessments, Bioko Island, January 2014.
Variables TOTAL Children 5  age 10 More than 10 years P-value
n % (95%CI) n % (95%CI) n % (95%CI)
MF in skin snips Negative 542 100 (CI95%: 99.3–100) 124 100 (CI95%: 97.1–100) 418 100 (CI95%: 97.1–100) p<0.001*
Positive 0 0 (CI95%: 0–0.7) 0 0 (CI95%: 0–2.9) 0 0 (CI95%: 0–0.9)
Skin PCR Negative 532 97.9 (CI95%: 96.4–98.9) 123 100 (CI95%: 97.1–100) 409 97.4 (CI95%: 95.4–98.6) 0.056
Positive 11 2 (CI95%: 1.1–3.6) 0 0 (CI95%: 0–2.40) 11 2.6 (CI95%: 1.4–4.6)
OV16-IgG4- ELISA Negative 473 89.1 (CI95%: 86.1–91.5) 124 100 (CI95%: 97.1–100) 349 85.7 (CI95%: 82–89) p<0.001
Positive 43 8.1 (CI95%: 6.1–10.7) 0 (CI95%:0–2.38) 0 (CI95%: 0–2.9) 43 10.6 (CI95%:7.8–13.9)
Undefined 15 2.8 (CI95%: 1.7–4.6) 0 0 (CI95%: 0–2.9) 15 3.7 (CI95%:2.1–6)
*Yates corrected chi square
doi:10.1371/journal.pntd.0004829.t003
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As expected, clinical and lab features were more common in adults than in younger groups.
Moreover, younger group was also less likely to be involved in preventive measures. These
observations also support previous evidence that repeated ivermectin treatments contribute to
the reduction in transmission/prevalence of onchocerciasis as well as in the intensity of infec-
tion [21,22].
Clinical study
Overall, we found a low number of individuals presenting clinical cutaneous manifestations of
onchocerciasis in our study, and most of them were adults, as expected. Pruritus was the most
common symptom, and only a few individuals pointed out suffering onchocerciasis specific
cutaneous lesions (mainly leopard skin and onchodermatitis). Moreover, we found a very low
number of onchocercal nodules carriers, which is coherent with the hypoendemic situation in
Bioko Island.
O. volvulus transmission in Bioko Island focus has been extensively documented since 1990
to date [14]. In a survey carried out in the mid 80’ in the Island of Bioko the 28.8% of the study
population presented with dermatitis, pigmentation changes and cutaneous atrophy [23]. The
global prevalence of nodules was 27.2%. This research showed that onchocerciasis was wide-
spread over the Island, with a high rate of population at risk of infection.
More recent data (1998) showed that prevalence of skin depigmentation, the proxy of long-
standing infection of onchocerciasis in the community, was 9.4%, with a reduction of 7.7%
after eight years of vertical ivermectin distribution [15]. In this study, it was pointed out that
carriers of nodules in children aged 0–4 years decreased 2.6 times, while no significant changes
were observed in other age groups [10]. This result reflected a reduction in onchocerciasis
Table 4. Preventive treatment by age Bioko Island, Equatorial Guinea, January 2014.
Variables Total Children 5 age
 10
More than 10 years p value
n % n % n %
RISK FACTORS
Have you ever taken ivermectin Yes 263 49.0 30 24.2 233 56.4 p<0.001
No 274 51.0 94 75.8 180 43.6
How many times in the last 5 years? More than 2 times 151 28.0 11 8.9 140 34.0 p<0.001
2 or less times 82 15.6 19 15.3 63 15.3
Never 303 50.7 94 75.8 209 50.7
Last time of ivermectin intake* Last year (2013/14) 111 41.7 21 70.0 90 38.1 0.002
More than one year ago 116 43.6 9 30.0 107 45.3
Don´t know/don´t answer 39 14.7 0 0.0 39 16.5
Ivermectin distributor* Health community distributor 164 65.6 23 85.2 141 63.2 0.023
Others 86 34.4 4 14.8 82 36.8
Reasons for not taking ivermectin Never had the disease 46 20.5 17 21.8 29 19.9 p<0.001
Absent at home 32 14.3 8 10.3 24 16.4
Lack of information 67 29.9 12 15.4 55 37.7
Age 37 16.5 32 41.0 5 3.4
Lack of access to drug 26 11.6 7 9.0 19 13.0
Others 16 7.1 2 2.6 14 9.6
*Only those who have ever taken ivermectin
doi:10.1371/journal.pntd.0004829.t004
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general transmission after several cycles of ivermectin distribution and vector elimination in
Bioko Island.
The impact of ivermectin on OCD in onchocerciasis endemic countries has been described in
the literature [24]. A multi-country study by Ozoh et al (2011) in meso and hyperendemic com-
munities of seven study sites in Cameroon, Sudan, Nigeria and Uganda showed a substantial
reduction in itching and all forms of OCD after five or six years of CDTI, including a reduction
in nodules [24]. Low rates of nodule prevalence can also found in countries with long history of
onchocerciasis control activities, such as most areas in Malawi, Kenya and Rwanda [25].
In our study, we observed most cases presenting itching and OCDmanifestations (including
nodules) were older than 10 years old, and depigmentation was exclusive of adults. Linkages
between OCD and age have been well documented [24]. Age is considered to be a risk factor
for depigmentation while reactive skin lesions overall have been described to be linked with
younger ages [26].
Parasitological, serological and molecular study
No positive MF skin snip assessments were found in our study population. Only one individual
was found to be positive for O. volvulus in skin by PCR. Moreover, almost 8% of individuals
were positive for IgG4 antibodies for Ov16 by using ELISA test. None of them were children.
Since the introduction of ivermectin distribution in 1987 in Bioko Island, an increasing
number of communities have been enrolled into the treatment programme, resulting in a sub-
stantial reduction in disease prevalence [14]. Data from 1989 showed that overall prevalence
(measured through MF skin snips assessment) and mean microfilarial density in Bioko Island
were 75.2% (range 51.9% to 87.1%) and 32.2 mf/snip respectively [15]. Later on, Mas et al
described a reduction in prevalence to 38.4% after eight years of treatment with ivermectin
(from 1989 to 1998) [15]. In this study, both prevalence and intensity of infection dropped
among the children under 5 years who had never been treated with an anti-filarial drug, sug-
gesting an indirect effect of ivermectin treatment towards younger groups. Similarly, studies in
Burundi [27] and Cameroon [28] have also shown a high reduction in prevalence and the
intensity of microfilaridermia in young children who have never received ivermectin, but lived
in four annual rounds of mass ivermectin treated communities.
The most recent available data from the Equatoguinean MoH (2013) showed a prevalence
of 0–3% in Bioko Island by MF skin snip assessment. This is coherent with the parasitological
results in our study.
Both microscopic detection of MF in skin snips and nodular palpation are useful epidemiolog-
ical tools in the field for diagnosis and monitoring of onchocerciasis prevalence in many endemic
countries [21,29–31]. Nevertheless, improved methods are needed for those areas with lower
infection prevalences, which might be close to elimination [13]. Determining IgG4 antibodies for
parasite-specific 16 kDa antigen (Ov16) is a recognized epidemiological tool to certificate the
interruption of onchocerciasis transmission in endemic countries [32–35]. According to recent
recommendations fromWHO (2016), the critical threshold for interruption or elimination of
transmission is the upper bound of the 95% confidence interval of less than 0.1% confirmed sero-
positivity to Ov-16 in children under 10 years of age [7]. In our study, the absence of positive
cases for IgG4 antibodies for Ov16 by using ELISA in children younger than 10 years old suggest
that the interruption of transmission might have been achieved in Bioko Island. However, the
sample size should be increased to 2,000 children, in order to meet theWHO requirement
needed to verify the interruption of onchocerciasis transmission [7].
Only one case was positive for O. volvulus by PCR, while the rate of onchocerciasis exposure
by IgG4 antibodies was remarkably higher. The unique positive case by PCR came from a rural
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community in Riaba district, usually not targeted by CDTI. Surprisingly, this case´ serological
test was negative, thus it might be a new infection. In a study carried out by Evans et al in Nige-
ria, the prevalence of onchocerciasis in children was also higher when measured by IgG4 anti-
bodies than with skin snip. Probably, these infections were below the sensitivity of a skin snip.
Other possible explanation is that their antibody response fitted a recent exposure rather than
a patent one [35]. Molecular technics based on PCR have demonstrated to be more sensitive
than skin snip microscopy or nodule palpation for detecting onchocerciasis [13,20]. In future
research, the use of PCR in skin snips from children who are Ov16 positive may be considered
as a confirmatory test.
Preventive practices
The mentioned remarkable decrease on onchocerciasis prevalence in Bioko Island happened in
spite of a moderate current involvement in preventive practices in the community. We found
that more than half the population had never taken ivermectin. Among those who had taken
ivermectin, most of them received the drug from a community distributor. The most important
identified reason for not taking ivermectin included lack of information, followed by not suffer-
ing the disease.
Previous research from APOC (2008) highlighted a progressive increase in ivermectin ther-
apeutic coverages in Bioko in the last years [16]. According to the most recent data from the
Equatoguinean MoH, 80% of therapeutic coverage was reached during 2013 ivermectin cam-
paign. It should be taken into account that this assessment was only performed in sentinel sites
while our analysis but the whole geographical territory of Bioko Island. This might explain dif-
ferences with our results.
Weaknesses in targeting younger ages (< 10 years old) were also identified as less than one
fourth of the children had ever taken the drug. Within this group, age was identified as the
main reason only in less than half.
Bearing in mind that ivermectin distribution campaigns target children after 5 years, our
findings suggest a reduction in community participation in ivermectin campaigns as success in
control program is achieved. This could be explained by a decrease on risk perception [36] or a
relaxation of the control program activities due to financial constraints.
Evidence that long-term ivermectin treatment alone might interrupt and eliminate onchocer-
ciasis in African countries has been well documented [22,34,35]. Overall, our findings support
that interruption of transmission might have been achieved in Bioko Island, and interruption of
ivermectin distribution could be considered in the near future. Nevertheless, decisions about
ceasing CDTI activities in Bioko Island should be cautious in order to avoid recrudescence. This
situation has been described in some neighbouring countries such as Cameroon after more than
a decade of onchoderciasis control activities, which showed a reduction of meso- and hyperen-
demic onchocerciasis areas to hypoendemic areas. Nevertheless, transmission appears to con-
tinue in many areas as it was found that children under 10 years of age in the follow-up surveys
had positive skin snips for MF [28]. Considerations about when to interrupt ivermectine distri-
bution and initiate Post Treatment Survaillance (PTS) phase in Bioko Island are still unclear.
Decisions on that respect will require additional entomologic studies (not performed since 2008).
Moreover, extended serology studies with children of 10 years of age and under are needed in
order to reach at least a 2000 children population, according to WHO guidelines (2016) [7].
Limitations
Pre-intervention data on the prevalence and intensity of onchocerciasis infection were not
available in some of the assessed communities as background information in order to assess
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the long-term impact of ongoing CDTI program. Moreover, the sample size was not large
enough to draw definite conclusions about interruption of transmission in Bioko. Some limita-
tions related to the comprehension level of the questionnaire among the study population
should also be noted.
Regarding the Ov16 ELISA test, it is currently not known how long the IgG4 antibody
response to the Ov16 antigen persists in exposed individuals and specificities vary according to
authors. Cross-reactions withMansonella species have been described [37]. Finally, although
PCR is considered a highly sensitive test, it should be noted that cost would limit its use as reg-
ular epidemiological tool to apply on entire populations.
Conclusions
Our findings support the idea that Equatorial Guinea is moving fast towards elimination after
long term ivermectin distribution and the elimination of the vector Simulium yahense Bioko
form from Bioko Island in 2005, among other factors. Our results will contribute to strengthen
and optimize the current onchocerciasis control activities supported by the National Control
Program. Appropriate communication and health education strategies to reinforce participa-
tion in CDTI activities are essential to ensure progress towards onchocerciasis elimination in
the country.
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